Vistagen under investigation for securities litigation by Intellectia.AI

Litigation Investigation: Faruqi & Faruqi, LLP has initiated an investigation into potential claims against Vistagen Therapeutics, focusing on investors who bought securities between April 1, 2024, and December 16, 2025. They are encouraged to pursue lead plaintiff status by the March 16, 2026 deadline.
Stock Price Drop: Vistagen’s stock experienced a drastic decline of over 81% to $0.88 per share on December 17, 2025, following the announcement that the PALISADE-3 clinical trial had not met its primary efficacy goal. This plunge resulted in significant financial repercussions for investors.
False Statements Allegation: The lawsuit contends that Vistagen and its executives violated federal securities laws by disseminating false and deceptive information about the chances of the fasedienol trial’s success. They also neglected to reveal material adverse facts that artificially boosted the stock price.
Protection of Investor Rights: Faruqi & Faruqi suggests that individuals with pertinent information about Vistagen’s actions, such as whistleblowers or former employees, reach out to the firm to offer legal assistance and furnish details to support affected investors.

Legal Notification: The Gross Law Firm has issued a notification to Vistagen Therapeutics shareholders, urging those who purchased stock between April 1, 2024, and December 16, 2025, to contact the firm regarding potential lead plaintiff eligibility. This will facilitate their chances of recovering losses.
Unsatisfactory Trial Outcome: Vistagen’s revelation on December 17, 2025, that the PALISADE-3 trial had failed to attain statistical significance on its primary endpoint led to the stock price plummeting from $4.36 to $0.86. The substantial drop of over 80% severely shook investor confidence.
Shareholder Registration Deadline: Shareholders interested in partaking in the class action lawsuit must register by March 16, 2026, to ensure that they remain informed about case developments in real-time, protecting their rights throughout the legal proceedings.
Firm Background: The Gross Law Firm is a well-regarded class action law entity dedicated to safeguarding investors who have incurred losses due to misinformation and unethical business behaviors, underlining the importance of companies adhering to ethical business standards.

Class Action Initiation: Robbins LLP prompts investors to remain vigilant about a class action filed for those who acquired Vistagen Therapeutics (NASDAQ:VTGN) common stock between April 1, 2024, and December 16, 2025. This poses considerable legal risks that could destabilize shareholder trust.
Misrepresentation Allegations: The lawsuit alleges that Vistagen misled investors about the efficiency of the Fasedienol trial, prompting shareholders to purchase stock at artificially inflated prices. This highlights fundamental shortcomings in the company’s transparency and disclosure practices.
Unfavorable Trial Results: Vistagen’s announcement on December 17, 2025, that the PALISADE-3 trial had not shown significant improvement on the primary endpoint resulted in a substantial decline in the stock price from $4.36 to $0.86, a reduction of over 80%, reflecting skepticism about the company’s future.
Investor Recommendations: Investors are advised to submit their applications to serve as lead plaintiffs in the class action by March 16, 2026, stressing the importance of enhanced corporate governance and shareholder rights.

Class Action Lawsuit: Bragar Eagel & Squire has initiated a class action suit against Vistagen in the U.S. District Court for the Northern District of California on behalf of shareholders who bought shares between April 1, 2024, and December 16, 2025. The deadline for lead plaintiff applications is March 16, 2026.
Misleading Statements Allegation: The lawsuit accuses Vistagen of issuing overly optimistic statements while concealing unfavorable facts about the Phase 3 PALISADE-3 trial of fasedienol, an investigational solution for social anxiety disorder.
Stock Price Decline: Following the December 17, 2025 announcement that the PALISADE-3 trial missed its primary endpoint, Vistagen’s stock plummeted from $4.36 to $0.86, registering an over 80% decline leading to substantial losses for investors.
Legal Aid Available: Investors impacted by these events are urged to connect with the law firm to gain clarity on their rights and potential claims without incurring any consultations costs, reflecting the firm’s dedication to safeguarding investor interests.

Notification of Lawsuit: The Gross Law Firm has dispatched a notice to Vistagen Therapeutics shareholders, advising individuals who purchased shares between April 1, 2024, and December 16, 2025, to engage with the firm concerning their potential selection as lead plaintiffs for recovery participation.
Trial Failure Ramifications: On December 17, 2025, the disclosure that Vistagen’s PALISADE-